Biogen (BIIB) Well Positioned After FDA Grants Priority Review - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $350.00 price target on Biogen (NASDAQ: BIIB), citing the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
